University of California San Francisco
Give to UCSF
Often deadly “triple-negative” breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, UCSF reports.
A team of researchers at UCSF is incorporating genomics into a broad group of potential factors that can help clinicians better understand which patients are at greatest risk for persistent postsurgical pain and how to better prevent or treat it.
<p>The U.S. Food and Drug Administration is issuing new recommendations for breast cancer trials that are based in part on groundbreaking, national breast cancer research led by UCSF.</p>
Scientists from the University of Helsinki, Finland, and UCSF have identified a cleaver-wielding protein that frees some tumor cells, allowing them to further misbehave. The discovery points to a new target for therapy.
During a decade of receiving mammograms, more than half of cancer-free women will be among those summoned back for more testing because of false-positive results, and about one in 12 will be referred for a biopsy.
<p>African American women have lower breast cancer survival rates than white women and University of California, San Francisco (UCSF) scientists are studying why – as well as how to increase their life spans.</p>
Taking an innovative path toward personalized medicine, scientists for the first time will be able to eliminate – at an early point in a clinical trial — experimental drugs that show poor efficacy, dramatically shortening the time it takes to get the right medication to the right patient with breast cancer.
A nationwide study of over 280,000 women showed that postmenopausal women who are overweight or obese have advanced breast cancer at significantly higher rates than women of normal weight or less than normal weight.